Published • loading... • Updated
On the Eve of Yimufeng Bio's Hong Kong Stock Exchange IPO, a Clinical Trial Participant Died.
Summary by 大纪元 Epoch Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Recently, the death of a CAR-T clinical trial participant at Shenzhen EmoFeng Biotechnology Co., Ltd. (hereinafter referred to as "EmoFeng") has thrust the company, which is currently pursuing a Hong Kong IPO, into the public spotlight. In February of this year, EmoFeng initially submitted its listing application to the Hong Kong Stock Exchange, but the application lapsed on August 13. On August 18, EmoFeng resubmitted its application, intending…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
